



CANCER_x NEW APPROACHES TO COMMERCIALIZING BIOMEDICAL RESEARCH

A conference of the MIT Laboratory for Financial Engineering[†]
In collaboration with the National Cancer Institute
and with the participation of the American Cancer Society

October 26-28, 2016
Cambridge, MA

Wednesday, October 26

- 12:00 – 4:00** **Optional Executive Education Session: Basic Financial Analysis for the Life Sciences Professional**
Location: Koch Institute at MIT, 500 Main Street, Cambridge, MA
Andrew W. Lo, MIT
- 5:00 – 6:00** **Registration Check-In and Cocktails**
Location: Marriott Hotel, 50 Broadway (2 Cambridge Center), Cambridge, MA
- 6:00 – 8:00** **Welcome Dinner**
Welcome Remarks: **Andrew Lo**, MIT
Opening Remarks: **Greg Simon**, Cancer Moonshot Task Force
Special Presentation: **Parag Mallick**, Canary Center at Stanford

Thursday, October 27

Location: Samberg Conference Center at MIT, 7th Floor, 50 Memorial Drive (building E52 in MIT terms), Cambridge, MA (entrances on Memorial Drive and Wadsworth Street)

- 8:00 – 8:30** **Registration Check-In and Continental Breakfast**
- 8:30 – 9:00** **Welcome and Conference Background and Objectives**
Andrew W. Lo, MIT
- 9:00 – 10:30** **Session 1 – Where Are We Now, and Where Do We Want to Be?**
Martin Friedman, Pharmakon Advisors; **Ansbert Gadicke**, MPM Capital; **JC Gutierrez-Ramos**, Synlogic; **Sean Khozin**, FDA; **Marty Tenenbaum**, Cancer Commons; **Jake Xia**, Harvard Management Company
- 10:30 – 11:00** **Break**
- 11:00 – 12:30** **Session 2 – New and Emerging Business Models 1: Public-Private Partnerships**
Terrance Coyne, Royalty Pharma; **Jose Maria Fernandez**, Spain's Treasury Department; **Neil Littman**, California Institute for Regenerative Medicine; **Chandra Ramanathan**, Bayer; **Theodore Schenkelberg**, Human Vaccines Project; **Jonathan Stamler**, Harrington Discovery Institute
- 12:30 – 2:00** **Lunch**
Fireside Chat with **Phillip A. Sharp**, MIT
Moderated by **Janet Wu**

[†] To encourage free and open discussion throughout the course of the conference, the Chatham House Rule will apply: Participants are free to use the information received, but neither the identity nor affiliation of the speaker(s), nor that of any other participant, may be revealed. In addition, members of the press have not been invited to attend.

- 2:00 – 3:30** **Session 3 – Innovations and Challenges in Translation and Clinical Trial Design**
Chris Austin, NCATS; **Scott Berry**, Berry Consultants; **Laura Esserman**, UCSF; **Jonathan Hirsch**, Syapse; **Monique Mansoura**, MIT; **Murray Sheldon**, FDA
- 3:30 – 4:00** **Break**
- 4:00 – 5:45** **Session 4 – Establishing Criteria: Analytics, Modeling, Structures, and Ratings**
David Agus, USC; **Ronald Borod**, DLA Piper; **Winston Chang**, S&P Global Ratings; **Mark Gordon**, Informa; **Nick Marko**, Geisinger Health System; **Tomas Philipson**, University of Chicago; **Roger Stein**, MIT
- 5:45 – 6:00** **Day 1 Conference Wrap-Up**
- 6:00 - 8:00** **Dinner**
Location: Marriott Hotel, 50 Broadway (2 Cambridge Center), Cambridge, MA
Fireside Chat with **Bob Beall**, Cystic Fibrosis Foundation
Moderated by **Janet Wu**

Friday, October 28

Location: Samberg Conference Center at MIT, 7th Floor, 50 Memorial Drive (building E52 in MIT terms), Cambridge, MA (entrances on Memorial Drive and Wadsworth Street)

- 8:00 – 8:30** **Continental Breakfast**
- 8:30 – 10:00** **Session 5 – Lessons Learned**
Christiana Bardon, Burrage Capital; **Anna Barker**, Arizona State University; **Jonathan Benjamin**, Amgen; **Howard Fingert**, Takeda
- 10:00 – 10:30** **Break**
- 10:30 – 12:00** **Session 6 – New and Emerging Business Models 2: Foundations, Patient Advocates, and Other Mission-Driving Organizations**
Parag Mallick, Canary Center at Stanford; **Larry Norton**, Memorial Sloan Kettering Cancer Center; **Julien de Salaberry**, The Global Cancer Research and Commercialisation Fund; **Lara Sullivan**, Pfizer; **Laura Thrall**, CureSearch for Children’s Cancer
- 12:00 – 1:30** **Lunch**
Keynote Speaker: **Chris Viehbacher**, Gurnet Point Capital
- 1:30 – 3:00** **Session 7 – New and Emerging Business Models 3: Private Sector Innovations**
Neil Kumar, BridgeBio; **Andrew Lee**, UBS; **Amy Schulman**, Polaris Partners; **Mayukh Sukhatme**, Roivant Sciences; **Bill Symonds**, Roivant Sciences
- 3:00 – 3:30** **Break**
- 3:30 – 5:00** **Session 8 – Convergence: Innovations in Academia and Commercialization**
Kevin Grimes, Stanford University School of Medicine; **Marc Goldberg**, BioVentures Investors; **Lita Nelsen**; **Jon Soderstrom**, Yale
- 5:00 – 5:30** **Day 2 Conference Wrap-Up**